Karch Christopher P, Burkhard Peter
The Institute of Materials Science, 97 North Eagleville Road, Storrs, CT 06269, United States.
The Institute of Materials Science, 97 North Eagleville Road, Storrs, CT 06269, United States; Department of Molecular and Cell Biology, 93 North Eagleville Road, Storrs, CT 06269, United States.
Biochem Pharmacol. 2016 Nov 15;120:1-14. doi: 10.1016/j.bcp.2016.05.001. Epub 2016 May 6.
Vaccines have been the single most significant advancement in public health, preventing morbidity and mortality in millions of people annually. Vaccine development has traditionally focused on whole organism vaccines, either live attenuated or inactivated vaccines. While successful for many different infectious diseases whole organisms are expensive to produce, require culture of the infectious agent, and have the potential to cause vaccine associated disease in hosts. With advancing technology and a desire to develop safe, cost effective vaccine candidates, the field began to focus on the development of recombinantly expressed antigens known as subunit vaccines. While more tolerable, subunit vaccines tend to be less immunogenic. Attempts have been made to increase immunogenicity with the addition of adjuvants, either immunostimulatory molecules or an antigen delivery system that increases immune responses to vaccines. An area of extreme interest has been the application of nanotechnology to vaccine development, which allows for antigens to be expressed on a particulate delivery system. One of the most exciting examples of nanovaccines are rationally designed protein nanoparticles. These nanoparticles use some of the basic tenants of structural biology, biophysical chemistry, and vaccinology to develop protective, safe, and easily manufactured vaccines. Rationally developed nanoparticle vaccines are one of the most promising candidates for the future of vaccine development.
疫苗一直是公共卫生领域最为重大的进步,每年预防数百万人发病和死亡。传统上,疫苗研发主要集中在全病原体疫苗,即减毒活疫苗或灭活疫苗。虽然全病原体疫苗对许多不同的传染病都很有效,但生产成本高昂,需要培养病原体,且有可能在宿主中引发与疫苗相关的疾病。随着技术的进步以及开发安全、经济高效候选疫苗的需求,该领域开始专注于开发重组表达抗原,即亚单位疫苗。虽然亚单位疫苗更易于耐受,但其免疫原性往往较低。人们已尝试通过添加佐剂来增强免疫原性,佐剂可以是免疫刺激分子或能增强对疫苗免疫反应的抗原递送系统。纳米技术在疫苗研发中的应用是一个备受关注的领域,它能使抗原在颗粒递送系统上表达。纳米疫苗最令人兴奋的例子之一是合理设计的蛋白质纳米颗粒。这些纳米颗粒利用结构生物学、生物物理化学和疫苗学的一些基本原理来开发具有保护性、安全性且易于生产的疫苗。合理开发的纳米颗粒疫苗是未来疫苗研发中最有前景的候选疫苗之一。